Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
222
resultados
Última actualización
05/02/2026 [06:51:00]
Resultados 200 a 222 de 222
Resumen de: US20260021175A1
The present disclosure relates to RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and PIV1 HN protein mutants, nucleic acids or vectors encoding them, compositions comprising a RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and/or PIV1 HN nucleic acid or combinations thereof, and uses thereof.
Resumen de: US20260021066A1
The present application is generally directed to methods for chelating calcium deposits within calcified blood vessels, as well as methods and compositions for use in regulating various senescence-related inflammatory pathways.
Resumen de: US20260021138A1
The present invention is related to the methods for obtaining compositions of extracellular vesicles and particles for providing an anticancer activity which consists of recognising and eliminating cancerous cells. The compositions are obtained by a set of methods that include immune cell stimulation by Toll-like receptor agonist, microenvironment stiffness and adhesion peptides, extracellular vesicle and particle collection, decreasing size of large extracellular vesicles for applicability adaptation and loading of an anticancer agent for delivery to cancer cells.
Resumen de: WO2026020171A2
The present disclosure provides CAR (chimeric antigen receptor) constructs, T cell populations having the CAR(s), and methods of treating cancer with the T cell populations.
Resumen de: WO2026017913A1
A nanoparticle comprising a diblock polymer comprising a first component covalently bound via a linker to a second component; wherein said first component is an oligomer comprising at least 50 mol% L-5 guluronic acid residues or at least 50 mol% galacturonic acid residues and having a degree of polymerisation n where n is at least 3; said second component is a second polymer having no more than 30 mol% L-guluronic acid residues or galacturonic acid residues and having a degree of polymerisation of at least 4;10 wherein said nanoparticle comprises a chelator such as DOTA; wherein said nanoparticle comprises at least one metal ion such as a radionuclide or Gd ions.
Resumen de: US20260014244A1
The present disclosure belongs to the technical field of mRNA vaccines, and particularly relates to a respiratory syncytial virus (RSV) vaccine, and a preparation method therefor and use thereof. The vaccine provided by the present disclosure comprises RNA encoding an RSV F protein or a variant thereof. The vaccine can prevent an RSV infection and complications thereof.
Resumen de: CN121039138A
The invention discloses a compound having the following structure of formula (I) or a stereoisomer, salt or tautomer thereof, wherein R1, R2, R3, R4, R5, R6, G1, G2, x, y, n, z and w are as defined herein. Compositions comprising the compounds and their use in methods of treating disease are also described.
Resumen de: CN121039145A
The invention discloses a compound having the following structure of formula (I) or a stereoisomer, salt or tautomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y1 and Y2 are as defined herein. Pharmaceutical compositions and lipid nanoparticles comprising the compounds and their use in methods of treating disease are also described.
Resumen de: WO2026017865A1
The present invention relates to the field of lipid nanoparticles (LNP) and direct delivery of an active agent to a cell. It provides lipid nanoparticle constructs that are particularly useful for delivery of active agents, e.g., of RNA, preferably, mRNA, to cells. The lipid nanoparticle constructs comprise a specific neutral hydrophilic solid lipid nanpoparticle (SLP) and a targeting agent associated with the nanoparticle, e.g. a single domain antibody (sdAb), which may, for example target CD4. The lipid nanoparticle construct may comprise an active agent, and it may be used for targeting a cell such as a T cell. Pharmaceutical compositions comprising the nanoparticle constructs are also provided, in particular for use in targeting a cell. The invention also provides a composition or kit suitable for preparing the lipid nanoparticle construct of the invention.
Resumen de: WO2026019940A2
The present disclosure provides a composition containing a purified population of plant-derived exosome-like nanoparticles isolated from tissue of a vascular plant, wherein the exosome-like nanoparticles comprise a tuned cargo comprising a protein signature and an miRNA signature, wherein the tuned cargo of the plant-derived exosome-like nanoparticles is a result of exposure of the plant to combinations of abiotic stress conditions that cause the plant to modulate its signaling pathways and metabolism to ensure its survival in a challenging environment. The tuned cargo of the plant-derived exosome-like nanoparticles can modulate bioactivities of mammalian cells directly or indirectly. The present disclosure also provides a method for improving appearance of human skin and human hair health, including eyelashes and eyebrows, comprising applying a composition comprising the abiotically stressed plant-derived exosome-like nanoparticles containing the tuned cargo and a carrier; and applying the composition topically.
Resumen de: EP4682138A1
An object of the present invention is to provide a compound or a salt thereof, which constitutes a lipid composition capable of realizing a high nucleic acid encapsulation rate and excellent nucleic acid delivery in a case where mRNA is used; and a lipid composition, a pharmaceutical composition, and a delivery carrier, which are capable of realizing a high nucleic acid encapsulation rate and excellent nucleic acid delivery in a case where mRNA is used. According to the present invention, a compound represented by Formula (1) or a salt thereof is provided.In the formula, R<sup>1</sup> represents a hydrocarbon group having 1 to 24 carbon atoms, R<sup>2</sup> represents a hydrocarbon group having 1 to 6 carbon atoms, R<sup>3</sup> represents a hydrocarbon group having 6 to 24 carbon atoms and having a branched chain, R<sup>4</sup> and R<sup>5</sup> represent a hydrocarbon group having 1 to 6 carbon atoms, which may be substituted, R<sup>6</sup> represents a hydrogen atom or a hydrocarbon group having 1 to 18 carbon atoms, L represents *-O-C(O)- or *-C(O)O-, a represents an integer of 1 to 12, and b, c, and d represent an integer of 1 to 4.
Resumen de: EP4682169A1
Provided is an anti-Claudin18.2 nanobody or a binding fragment thereof. The antibody has a good specificity, and a Claudin18.2-targeting immune effector cell prepared using the antibody shows a good therapeutic effect in the treatment or amelioration of diseases having positive expression of Claudin18.2.
Resumen de: EP4681739A1
The present invention relates to the field of lipid nanoparticles (LNP) and direct delivery of an active agent to a cell. It provides lipid nanoparticle constructs that are particularly useful for delivery of active agents, e.g., of RNA, preferably, mRNA, to cells. The lipid nanoparticle constructs comprise a specific neutral hydrophilic solid lipid nanpoparticle (SLP) and a targeting agent associated with the nanoparticle, e.g. a single domain antibody (sdAb), which may, for example target CD4. The lipid nanoparticle construct may comprise an active agent, and it may be used for targeting a cell such as a T cell. Pharmaceutical compositions comprising the nanoparticle constructs are also provided, in particular for use in targeting a cell. The invention also provides a composition or kit suitable for preparing the lipid nanoparticle construct of the invention.
Resumen de: AU2024236558A1
The present disclosure describes improved LNP-based nucleobase editing systems and therapeutics for use in treating a disease. In particular, the disclosure describes improved LNPs, including novel and improved ionic lipids for making LNPs, that enhance the targeted delivery of LNP-based nucleobase editing systems and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced nucleobase editing systems and/or therapeutic agents.
Resumen de: WO2024189572A1
The present invention discloses carriers with an onco-suppressive agent and selectively directed to a tumoral target for the treatment of metastatic melanoma resistant to a target therapy.
Resumen de: WO2024192235A2
The present disclosure relates compositions comprising and/or encoding nanodegraders (ND) and methods of use thereof.
Resumen de: EP4678747A2
The present disclosure provides a double-stranded RNAi agent for targeting and regulating HBV gene expression and a use thereof. The double-stranded RNAi agent comprises an antisense strand and a sense strand complementary to the antisense strand forming a duplex region. The nucleotide sequence of the antisense strand is as shown in SEQ ID NO: 8, 11, or 13, or the nucleotide sequence of the antisense strand is a modified sequence of the sequence shown in SEQ ID NO: 8, 11, or 13. Results from cell and animal experiments demonstrate that the double-stranded RNAi agent provided in the present disclosure can significantly reduce the expression of one or more HBV genes, block the viral life cycle, and can be used to develop drugs for treating diseases related to HBV gene expression.
Resumen de: MX2025007492A
The present application discloses compounds of formula (I) and salts and stereoisomers thereof, wherein the variables are as defined in the description. Further disclosed in the present application are nanoparticle compositions comprising the compounds, salts thereof, or stereoisomers thereof, and a use of the nanoparticle compositions for delivering an active agent.
Resumen de: AU2024239507A1
Disclosed herein, in part, are pharmaceutical compositions comprising a prodrug of an antiviral agent and methods of using the same in the treatment of viral infections.
Resumen de: EP4682174A1
Provided is a universal influenza mRNA vaccine. The protein encoded by the universal influenza mRNA vaccine comprises a matrix protein 2 extracellular domain (M2e), a hemagglutinin (HA) stem LAH region and a nucleoprotein (NP) of an influenza A virus. In addition, further provided is the use of the universal influenza mRNA vaccine in a mouse animal model. The universal influenza mRNA vaccine can induce strong humoral immune and cellular immune responses, and can protect animal model mice against various influenza A viruses. The universal influenza mRNA vaccine is safe and effective, and has a rapid production platform.
Resumen de: WO2024192288A2
Described herein are methods, systems and compositions for the production and use of a class of highly branched, nanostructured particles, generally referred to herein as dendritic particles (DPs), synthesized from biodegradable materials that are specifically adapted for drug release in vivo.
Nº publicación: JP2026010063A 21/01/2026
Solicitante:
ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド
Resumen de: US2023201127A1
Lipid particles for nucleic acid delivery and clinical applications of same are provided. Accordingly there is provided a lipid particle comprising a cationic lipid encapsulating a nucleic acid sequence, wherein said nucleic acid sequence encodes a protein having a length of at least 500 amino acids, the cationic lipid being represented by Formula I, as defined in the specification.
BOPI
Sede Electrónica
